Deutetrabenazine
Deutetrabenazine
Deutetrabenazine (pronounced: doo-tet-ra-BEN-a-zeen) is a medication used primarily in the treatment of Huntington's disease and Tardive dyskinesia. It is a derivative of tetrabenazine and functions as a vesicular monoamine transporter 2 (VMAT2) inhibitor.
Etymology
The name "Deutetrabenazine" is derived from its parent compound, tetrabenazine, with the prefix "deute-" referring to the presence of deuterium, a stable isotope of hydrogen, in its molecular structure.
Pharmacology
Deutetrabenazine works by inhibiting VMAT2, a protein responsible for packaging neurotransmitters into vesicles for release into the synapse. By inhibiting this protein, deutetrabenazine reduces the amount of dopamine and other monoamines available for release, thereby reducing the symptoms of diseases characterized by excessive dopamine activity, such as Huntington's disease and tardive dyskinesia.
Related Terms
- Huntington's disease: A genetic disorder that causes progressive degeneration of nerve cells in the brain.
- Tardive dyskinesia: A side effect of certain medications, characterized by involuntary movements.
- Tetrabenazine: A medication used to manage movement disorders, and the parent compound of deutetrabenazine.
- Vesicular monoamine transporter 2 (VMAT2): A protein that packages neurotransmitters into vesicles for release into the synapse.
- Dopamine: A neurotransmitter associated with pleasure and reward in the brain.
External links
- Medical encyclopedia article on Deutetrabenazine
- Wikipedia's article - Deutetrabenazine
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski